US Patent

US9388134 — Compounds containing S-N-valeryl-N-{[2â²-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations

Method of Use · Assigned to Novartis AG · Expires 2026-11-08 · 0y remaining

Vulnerability score 93/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating cardiovascular or renal conditions with a specific combination of an angiotensin receptor antagonist and a NEPi.

USPTO Abstract

A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1723`	—
`U-1723`	—
`U-1723`	—
`U-1723`	—
`U-1723`	—

Patent Metadata

Patent number: US9388134
Jurisdiction: US
Classification: Method of Use
Expires: 2026-11-08
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.